Ley internacional sobre el cannabis

The same product can carry different legal identities in different countries. What one government treats as hemp, another may treat as a controlled substance, a medicine, or a banned import.

That mismatch repeats across banking, licensing, operations, ownership, and tax. A company that treats international cannabis like ordinary cross-border trade usually learns the difference fast, and at the worst possible time.

The biggest risk is the unexamined assumption. Companies assume that legal in two places means transferable between them. Product, money, ownership, and IP do not move that cleanly.

The recurring failure points are customs, product classification, banking, freight forwarding, and the local partner. The first three can stop a deal cold. A bad freight forwarder or local partner can do even more lasting damage, especially after capital has moved, confidential information has been shared, or product has shipped.

Yes, with the right structure and only between countries that permit the specific product and the specific transaction. Medical cannabis, industrial hemp, cannabinoid isolates, and finished products each travel under different rules. Currently, adult-use cannabis cannot be imported or exported.

Before anything ships, confirm the product classification, the THC limit, the import and export permits, the regulatory barriers within the importing country, such as EU GMP, and the customs treatment on both ends. Confirm that the exporting country and the importing country both allow the trade. One yes is not enough. It is also critical to have partners who work with you throughout the process. It is not uncommon for enforcement at the importing border to contradict the importing country’s regulations for cannabis.

Usually, but rarely as cleanly as companies expect. Many countries draw the line at THC content and then add conditions on product form, intended use, and health claims. Most countries do not permit the import of consumable cannabis products, outside the medical marijuana regulations. Despite robust markets for THCA and CBD beverages in Europe, THCA is illegal (just as it is in the U.S.) and CBD beverages live in a gray area.

A shipment can qualify as hemp at origin and arrive as a controlled substance. “Hemp is legal” is a slogan. It is not an import plan.

If you are willing to live in the gray area of European law, then maybe. It all depends on whether your CBD product is treated as a cosmetic, a food, a supplement, or a medicine.

The answer turns on details. Exact ingredients, extraction source, THC content, the health claims on the label, and the sales channel can each change the legal outcome. Two products that look identical on a shelf can sit on opposite sides of the law.

Customs is where many cross-border cannabis deals live or die. A product can be lawful to sell at home and still be detained, seized, or destroyed at the border. With cannabis this can even occur if the product is legal in the importing country. Most customs agents have broad authority to interpret laws and regulations, which can sometimes lead to holds at the border. For products that have a limited shelf life, this can be catastrophic. That is why the proper freight-forwarding company and insurance are critical.

Customs authorities scrutinize tariff classification, country of origin, THC content, labeling, importing-country regulations, and the qualifications of the importer. For cannabis goods, a small documentation error can produce delays, seizures, penalties, and destroyed inventory.

In many jurisdictions, yes, but cannabis investments usually draw heavier scrutiny than ordinary investments. Investors may face ownership caps, residency requirements, source-of-funds review, and background checks.

The analysis cannot stop at the target country. An investment that is lawful where the cannabis business operates can still create banking, tax, or immigration concerns in the investor’s home jurisdiction. The investor’s own country is part of the deal.

Test the actual business model, not the headline. “Is cannabis legal here?” is the easy question. The harder questions are whether your specific operation can secure the required licenses, import what it needs, hold the property it requires, and bank its revenue.

Hire legal, regulatory, and logistics professionals. Looking for the cheapest way to import your products into a foreign market will almost certainly create greater long-term costs. Make sure you vet everyone. Local partners, distributors, license holders, attorneys, regulatory advisors, and landlords carry risks that do not always show up in the statute. The wrong partner can do more damage than the wrong market.

International cannabis M&A demands more than standard corporate diligence. License history, regulatory approvals, banking relationships, tax position, and product compliance all need direct verification.

The dangerous items are often the ones the corporate records do not show. Undocumented regulatory problems, side agreements, unpaid taxes, and shaky license assumptions tend to surface after closing, when they belong to the buyer.

Yes. A standard domestic agreement leaves the cross-border cannabis company exposed.

The contract should assign import and export responsibility, fix product specifications and quality control, set governing law and dispute resolution, and state what happens when the law changes. In this industry, a vague contract can become a compliance failure, not just a commercial problem.

Sometimes, but banking remains one of the hardest parts of international cannabis work. Even where cannabis is legal, banks may reject cannabis-linked funds because of anti-money-laundering rules, correspondent banking exposure, or internal risk policy.

Build the banking path before you need it. Source-of-funds documentation, payment terms, and compliance files belong in the structure from day one, not after a wire transfer is frozen.

Sometimes, but almost never under one global campaign. Marketing rules for cannabis, hemp, and CBD products vary sharply by country.

Many jurisdictions restrict health claims, online advertising, influencer promotion, and packaging. Some prohibit marketing altogether. A campaign that clears review in one market can create a consumer protection or controlled substances problem in the next.

It is often one of the most valuable parts of the legal strategy. Brands, genetics, formulations, and trade secrets are frequently the real assets behind a cannabis business.

Trademarks, patents, plant variety rights, and confidentiality terms should be considered before market entry, and the key protections should be in place before a local partner, manufacturer, or competitor ever gets access to the brand, the genetics, or the formulations.

Often, yes. Arbitration can work well when parties are in different countries, assets are spread across borders, and the dispute requires confidentiality.

It only works if the contract is built correctly. Governing law, arbitral seat, rules, language, and enforceability all need to be addressed in advance. The parties also need to consider whether a cannabis-related claim will be recognized and enforced where the assets actually sit.

This is one of the defining risks of the industry. Regulations, agency positions, import rules, and enforcement priorities can shift quickly, including mid-deal.

Allocate that risk in writing. The contract should state what happens if a product becomes unlawful, a license is suspended, import rules tighten, or a party can no longer legally perform. Parties that skip these provisions often end up litigating a problem they could have priced, limited, or avoided at signing.

Cannabis expertise alone is not enough, and international business expertise alone is not enough. Cross-border cannabis work sits on top of both.

A company entering a foreign market needs coordinated advice on structure, licensing, customs, tax, IP, banking, and partner diligence. These issues connect to each other. Handling them in separate silos is how a deal that looks workable at signing comes apart later.

Harris Sliwoski brings together cannabis law and international business law, and the corporate, regulatory, customs, IP, and dispute experience that sits between them. That combination matters because international cannabis work is not just cannabis law and it is not just international law. It requires both.

Our cannabis practice has been nationally ranked by Chambers USA, and our Denver partner Christian Sederberg has been ranked in Band 1, Chambers’ top individual ranking in cannabis law. Several of our attorneys have also been named to Super Lawyers, and our international team has spent years helping companies operate, invest, and resolve disputes across borders.

We advise cannabis, hemp, CBD, and cannabinoid businesses on the legal issues that determine whether an international strategy can actually work: corporate structuring, regulatory compliance, customs, IP protection, foreign investment, M&A, and dispute resolution.

We represent companies, investors, buyers, sellers, manufacturers, and operators on the questions that determine execution. The goal is a structure that can survive regulatory scrutiny, commercial pressure, and the problems that usually show up after money has moved or product has shipped.

We help clients assess whether a proposed international cannabis strategy is legally viable, commercially realistic, and properly structured. That work runs from market-entry planning and entity formation through licensing strategy, partner diligence, supply and distribution agreements, customs analysis, trademark protection, M&A diligence, and dispute planning.

We also help clients identify risks before they become expensive. In cross-border cannabis deals, the worst problems often arise from assumptions made early: that a product can be imported, that a license covers the actual business model, that a local partner is trustworthy, that a bank will process the funds, or that IP can be protected later. Those assumptions should be tested before the company commits capital, inventory, or confidential information.

Early. Before entering the market, signing a local partner, moving money, shipping product, disclosing IP, or relying on a license.

Counsel brought in after a shipment is detained or a bank freezes the account is usually being asked to contain damage. The most valuable work happens before the problem is visible.